
## Shereen X Y Soon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8644681/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	World's First Experience Treating TASC II C and D Tibial Occlusive Disease Using the Selution SLR Sirolimus-Eluting Balloon: Six-Month Results From the PRESTIGE Study. Journal of Endovascular Therapy, 2021, 28, 555-566.	0.8	17
2	Early results of an Asian prospective multicenter VenaSeal real-world postmarket evaluation to investigate the efficacy and safety of cyanoacrylate endovenous ablation for varicose veins. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, 9, 335-345.e2.	0.9	14
3	Early (6 months) results of a pilot prospective study to investigate the efficacy and safety of sirolimus coated balloon angioplasty for dysfunctional arterio-venous fistulas: MAgicTouch Intervention Leap for Dialysis Access (MATILDA) Trial. PLoS ONE, 2020, 15, e0241321.	1.1	10
4	Utility of Sirolimus Coated Balloons for Salvaging Dysfunctional Arteriovenous Fistulae: One Year Results From the MATILDA trial. European Journal of Vascular and Endovascular Surgery, 2021, 62, 316-317.	0.8	8
5	Distribution of Peripheral Arterial Disease in Patients Undergoing Endovascular Revascularization for Chronic Limb Threatening Ischaemia: Insights from the Vascular Quality Initiative in Singapore. Vascular Specialist International, 2021, 37, 13.	0.2	7
6	The modified frailty index-11 predicts medium-term outcomes after endovascular revascularisation for chronic limb threatening ischaemia in Asian patients. Vascular, 2022, 30, 42-51.	0.4	7
7	An Observational Clinical Trial Examining the Effect of Topical Oxygen Therapy (Natrox <sup>â,,¢</sup> ) on the Rates of Healing of Chronic DiAbetic Foot Ulcers (OTONAL Trial). International Journal of Lower Extremity Wounds, 2021, , 153473462110536.	0.6	7
8	Slow-flow phenomena following lower limb paclitaxel- and sirolimus-coated balloon angioplasty in the setting of chronic limb threatening ischaemia—a case series. Quantitative Imaging in Medicine and Surgery, 2022, 12, 2058-2065.	1.1	7
9	Endovascular salvage of failing arterio-venous fistulas utilising sirolimus eluting balloons: Six months results from the ISABELLA trial. Journal of Vascular Access, 2021, , 112972982110670.	0.5	6
10	Intervention with selution SLRâ,,¢ Agent Balloon for Endovascular Latent Limus therapy for failing AV Fistulas (ISABELLA) Trial: Protocol for a pilot clinical study and pre-clinical results. Journal of Vascular Access, 2023, 24, 289-299.	0.5	5
11	Utility of the selution SLRâ,,¢ sirolimus eluting balloon to rescue failing arterio-venous fistulas – 12 month results of the ISABELLA Registry from Singapore. CVIR Endovascular, 2022, 5, 8.	0.4	5
12	Improving medical adherence and antithrombotic management for patients with chronic limb threatening ischaemia in Singapore. Annals of the Academy of Medicine, Singapore, 2021, 50, 795-797.	0.2	4
13	One-year outcome using cyanoacrylate glue to ablate truncal vein incompetence: A Singapore VenaSealâ,,¢ real-world post-market evaluation <i>s</i> tudy (ASVS). Phlebology, 2021, 36, 609-619.	0.6	3
14	Use of the helical SUPERAâ,,¢ stent and Passeo-18 Luxâ,,¢ drug-coated balloon to treat recurrent cephalic arch stenosis for dysfunctional brachiocephalic fistulas: 1 year results of the Arch V SUPERA-LUX study. Journal of Vascular Access, 2021, , 112972982110430.	0.5	3
15	Use of Blue Light in the Management of Chronic Venous Ulcer in Asian Patients: A Case Series. Cureus, 2021, 13, e17703.	0.2	3
16	Treatment of cephalic arch stenosis in dysfunctional arteriovenous fistulas with paclitaxel-coated versus conventional balloon angioplasty. CVIR Endovascular, 2021, 4, 80.	0.4	3
17	12-Months Results From the PRESTIGE Study Using Sirolimus Drug-Eluting Balloons in the Treatment of Complex BTK Tibial Atherosclerotic Lesions in CLTI Patients. Cardiovascular Revascularization Medicine, 2022, 43, 143-146.	0.3	3
18	Heal or no heel: Outcomes of ischaemic heel ulcers following lower limb revascularization from a multiâ€ethnic Asian Cohort in Singapore. International Wound Journal, 2020, 17, 2010-2018.	1.3	2

SHEREEN X Y SOON

#	Article	IF	CITATIONS
19	Re: "Do we need another modality for truncal vein ablation?―– What about microwave as an endothermal device?. Phlebology, 2021, 36, 414-415.	0.6	2
20	Utility of a novel high pressure non-compliant balloon for tibial atherosclerotic lesions in Asian patients with chronic limb threatening ischaemia. Vasa - European Journal of Vascular Medicine, 2020, 49, 475-482.	0.6	2
21	Re: Risk of Death and Amputation with Use of Paclitaxel-Coated Balloons in the Infrapopliteal Arteries for Treatment of Critical Limb Ischemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Vascular and Interventional Radiology, 2020, 31, 1029-1030.	0.2	1
22	Using a Syringe Pump During MOCA: a Good Idea but Doesn't Give the Required Flexibility for Effective Truncal Ablation. Vascular Specialist International, 2020, 36, 270-272.	0.2	1
23	Combination therapy using scoring and sirolimus drug-coated balloons during lower limb endovascular revascularization for chronic limb threatening ischaemia: A case series. SAGE Open Medical Case Reports, 2022, 10, 2050313X2210858.	0.2	1
24	Rangerâ"¢ paclitaxel-coated balloon versus conventional balloon angioplasty for treatment of failing arteriovenous fistulas and grafts in haemodialysis patients: A retrospective cohort study. Journal of Vascular Access, 2021, , 112972982110670.	0.5	1
25	Midterm outcomes (2 years) using the Venovoâ,,¢ and Sinus Obliquusâ,,¢ venous stents in the treatment of non-thrombotic and post-thrombotic iliac vein lesions – Results from a multi-centre Asian cohort. Phlebology, 2022, , 026835552210944.	0.6	1
26	One year clinical outcomes of Rutherford 6 chronic limb threatening ischemia patients undergoing lower limb endovascular revascularisation from Singapore. CVIR Endovascular, 2022, 5, .	0.4	1
27	Re: "Modification of protocol with one extra drop of endovascular cyanoacrylate improved closure rates in incompetent great saphenous veinsâ€â€"time to rethink the instructions for use for VenaSealâ"¢?. Phlebology, 0, , 026835552211088.	0.6	0